Evidence map›Paper›PMID 26341673›Full record

ReviewPediatric neurology2015

Glucose Transporter Type I Deficiency (G1D) at 25 (1990-2015): Presumptions, Facts, and the Lives of Persons With This Rare Disease.

Juan M Pascual, Gabriel M Ronen

2 registry-linked trialsAbstract readCase ReportsReview
In one paragraph

Review in Pediatric neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03041363 phase1completednot on this mapstarted 2017, after this paper: background citation

Treatment Development of Triheptanoin (C7) for Glucose Transporter Type I Deficiency (G1D): A Phase I Maximum Tolerable Dose Trial

TypeinterventionalSponsorJuan PascualRan2017 to 2017Enrolled12ConditionsEpilepsy, GLUT1DS1, Glut1 Deficiency Syndrome 1, Autosomal Recessive, Glucose Metabolism DisordersArmsTriheptanoin
NCT03181399 phase2completednot on this mapstarted 2018, after this paper: background citation

Dietary Treatment of Glucose Transporter Type 1 Deficiency (G1D)

TypeinterventionalSponsorUniversity of Texas Southwestern Medical CenterRan2018 to 2023Enrolled45ConditionsGLUT1DS1, Epilepsy, Glut1 Deficiency Syndrome 1, Autosomal Recessive, Glucose Metabolism DisordersArmsTriheptanoin
3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Article
  2. Article
  3. Neurological glycogen storage diseases and emerging therapeutics.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2024
    Review
  4. Article
  5. Article
  6. Red blood cells as glucose carriers to the human brain: Modulation of cerebral activity by erythrocyte exchange transfusion in Glut1 deficiency (G1D).Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2023
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Glucose transporters in brain in health and disease.Pflugers Archiv : European journal of physiology · 2020
    Review
  13. Article
  14. Review
  15. Therapeutic strategies for glucose transporter 1 deficiency syndrome.Annals of clinical and translational neurology · 2019
    Review
  16. Paroxysmal Movement Disorders: Recent Advances.Current neurology and neuroscience reports · 2019
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Juan M PascualRare Brain Disorders Program, Departments of Neurology and Neurotherapeutics, Physiology and Pediatrics, Eugene McDermott Center for Human Growth and Development/Center for Human Genetics, The University of Texas Southwestern Medical Center, Dallas, Texas. Electronic address: Juan.Pascual@UTSouthwestern.edu.
Gabriel M RonenDepartment of Pediatrics, McMaster Child Health Research Institute, McMaster University, Hamilton, Ontario, Canada.

Funding

NORTH AND CENTRAL TEXAS CTSA FOR PEDIATRIC RESEARCHUL1RR024982 · NCRR · UT SOUTHWESTERN MEDICAL CENTER · PI TOTO, ROBERT DANIEL · 2007 to 2011
$27.9M
UT Southwestern Center for Translational Medicine (UL1/KL2/TL1)UL1TR001105 · NCATS · UT SOUTHWESTERN MEDICAL CENTER · PI TOTO, ROBERT DANIEL · 2013 to 2017
$24.5M
The North American Mitochondrial Disease Consortium (NAMDC)U54NS078059 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HIRANO, MICHIO · 2011 to 2023
$17.5M
YTTRIUM HYPERPOLARIZATIONP41RR002584 · NCRR · UT SOUTHWESTERN MEDICAL CENTER · PI MASON, RALPH P. · 1985 to 2011
$14.3M
Normalized functional MRI in human brain disordersR01MH084021 · NIMH · UT SOUTHWESTERN MEDICAL CENTER · PI LU, HANZHANG · 2008 to 2017
$3.6M
Modulation of neural function in energy failureR01NS077015 · NINDS · UT SOUTHWESTERN MEDICAL CENTER · PI PASCUAL, JUAN M. · 2012 to 2016
$1.7M
Modulation of brain activity by control of the inspired airR01NS067015 · NINDS · UT SOUTHWESTERN MEDICAL CENTER · PI LU, HANZHANG · 2010 to 2013
$1.5M
NCATS NIH HHS UL1 TR001105NCRR NIH HHS P41 RR002584NCRR NIH HHS RR002584NCRR NIH HHS RR024982NCRR NIH HHS UL1 RR024982NIMH NIH HHS MH084021NIMH NIH HHS R01 MH084021NINDS NIH HHS NS067015NINDS NIH HHS NS077015NINDS NIH HHS NS078059NINDS NIH HHS R01 NS067015NINDS NIH HHS R01 NS077015NINDS NIH HHS U54 NS078059
6 · The paper itself

Abstract

backgroundAs is often the case for rare diseases, the number of published reviews and case reports of glucose transporter type I deficiency (G1D) approaches or exceeds that of original research. This can indicate medical interest, but also scientific stagnation.

methodsIn assessing this state of affairs here, we focus not on what is peculiar or disparate about G1D, but on the assumptions that have reigned thus far undisputed, and critique them as a potential impediment to progress. To summarize the most common G1D phenotype, we trace the 25-year story of G1D in parallel with the natural history of one of two index patients, identified in 1990 by one of us (G.M.R.) and brought up to date by the other (J.M.P.) while later examining widely repeated but little-scrutinized statements. Among them are those that pertain to assumptions about brain fuels; energy failure; cerebrospinal glucose concentration; the purpose of ketogenic diet; the role of the defective blood-brain barrier; genotype-phenotype correlations; a bewildering array of phenotypes; ictogenesis, seizures, and the electroencephalograph; the use of mice to model the disorder; and what treatments may and may not be expected to accomplish.

resultsWe reach the forgone conclusion that the proper study of mankind-and of one of its ailments (G1D) -is man itself (rather than mice, isolated cells, or extrapolated inferences) and propose a framework for rigorous investigation that we hope will lead to a better understanding and to better treatments for this and for rare disorders in general.

conclusionsThese considerations, together with experience drawn from other disorders, lead, as a logical consequence, to the nullification of the view that therapeutic development (i.e., trials) for rare diseases could or should be accelerated without the most vigorous scientific scrutiny: trial and error constitute an inseparable couple, such that, at the present time, hastening the former is bound to precipitate the latter.

Indexed as

AdultAnimalsBrainFemaleGlucose Transporter Type 1HumansMetabolism, Inborn ErrorsRare DiseasesGlucose Transporter Type 1blood brain barrierG1DGlut1 deficiencynatural historytriheptanoin

Identifiers

PMID26341673
PMCPMC4609610

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.